JP2010501594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501594A5 JP2010501594A5 JP2009525853A JP2009525853A JP2010501594A5 JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5 JP 2009525853 A JP2009525853 A JP 2009525853A JP 2009525853 A JP2009525853 A JP 2009525853A JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5
- Authority
- JP
- Japan
- Prior art keywords
- variable region
- glycoprotein
- hcv
- modified
- linker sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006904635A AU2006904635A0 (en) | 2006-08-25 | Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus | |
| AU2006904635 | 2006-08-25 | ||
| AU2006906090A AU2006906090A0 (en) | 2006-11-01 | Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment | |
| AU2006906090 | 2006-11-01 | ||
| AU2006906282 | 2006-11-10 | ||
| AU2006906282A AU2006906282A0 (en) | 2006-11-10 | Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment | |
| PCT/AU2007/001221 WO2008022401A1 (en) | 2006-08-25 | 2007-08-24 | Recombinant hcv e2 glycoprotein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014185095A Division JP5999524B2 (ja) | 2006-08-25 | 2014-09-11 | 組換えｈｃｖｅ２糖タンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2010501594A JP2010501594A (ja) | 2010-01-21 |
| JP2010501594A6 JP2010501594A6 (ja) | 2010-04-15 |
| JP2010501594A5 true JP2010501594A5 (enExample) | 2010-10-07 |
| JP5674310B2 JP5674310B2 (ja) | 2015-02-25 |
Family
ID=39106399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525853A Expired - Fee Related JP5674310B2 (ja) | 2006-08-25 | 2007-08-24 | 組換えｈｃｖ ｅ２糖タンパク質 |
| JP2014185095A Expired - Fee Related JP5999524B2 (ja) | 2006-08-25 | 2014-09-11 | 組換えｈｃｖｅ２糖タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014185095A Expired - Fee Related JP5999524B2 (ja) | 2006-08-25 | 2014-09-11 | 組換えｈｃｖｅ２糖タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8535686B2 (enExample) |
| EP (1) | EP2061805B1 (enExample) |
| JP (2) | JP5674310B2 (enExample) |
| KR (1) | KR101500017B1 (enExample) |
| CN (1) | CN101563362B (enExample) |
| AU (1) | AU2007288129B2 (enExample) |
| CA (1) | CA2661814A1 (enExample) |
| WO (1) | WO2008022401A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2061805B1 (en) * | 2006-08-25 | 2020-02-12 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | Recombinant hcv e2 glycoprotein |
| US9758794B2 (en) | 2008-04-22 | 2017-09-12 | Rutgers, The State University Of New Jersey | HCV E2 construct compositions and methods |
| CA2722423A1 (en) * | 2008-04-22 | 2009-10-29 | Rutgers, The State University | Hcv e2 construct compositions and methods |
| CA2726914A1 (en) * | 2008-06-03 | 2009-12-10 | Okairos Ag | A vaccine for the prevention and therapy of hcv infections |
| CA2658714A1 (en) * | 2009-03-17 | 2010-09-17 | Thomas Krey | Hcv-derived polypeptides and uses thereof |
| CN102199613A (zh) * | 2010-03-25 | 2011-09-28 | 国立大学法人东京大学 | 感染性丙型肝炎病毒高生产hcv突变体及其应用 |
| AU2011286168B2 (en) | 2010-08-04 | 2015-05-28 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified hepatitis C virus proteins |
| KR20140036127A (ko) * | 2010-11-26 | 2014-03-25 | 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 | 조성물 및 방법 |
| US20130084301A1 (en) * | 2011-08-30 | 2013-04-04 | Steven Foung | Cluster of Neutralizing Antibodies to Hepatitis C Virus |
| CN103102394B (zh) * | 2013-02-27 | 2014-06-25 | 北京大学人民医院 | 丙型肝炎病毒b细胞表位肽puhi49及其应用 |
| EP3519424A4 (en) * | 2016-09-29 | 2020-06-03 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | ASSEMBLED GLYCOPROTEINS |
| US11008368B2 (en) * | 2019-07-26 | 2021-05-18 | The Scripps Research Institute | Engineered HCV E2 immunogens and related vaccine compositions |
| US20230181726A1 (en) * | 2020-05-11 | 2023-06-15 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide |
| CN112730851B (zh) * | 2021-03-31 | 2021-06-22 | 南京立顶医疗科技有限公司 | 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2201703A1 (en) * | 1994-10-21 | 1996-05-09 | Geert Maertens | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| AU1462300A (en) | 1998-11-05 | 2000-05-22 | Board Of Trustees Of The Leland Stanford Junior University | Human pan-hcv human monoclonal antibodies |
| AU7602800A (en) | 1999-09-23 | 2001-04-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof |
| WO2002022155A1 (en) | 2000-09-13 | 2002-03-21 | Hawaii Biotechnology Group, Inc. | Immunogenic composition of hepatitis c and methods of use thereof |
| AR035867A1 (es) * | 2001-04-24 | 2004-07-21 | Innogenetics Nv | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e |
| IL145440A0 (en) * | 2001-09-13 | 2002-06-30 | Xtl Biopharmaceuticals Ltd | Synthetic hcv envelope proteins and their use for vaccination |
| JP5138230B2 (ja) * | 2004-01-07 | 2013-02-06 | サード・ウェーブ・テクノロジーズ・インク | Ｃ型肝炎ウイルスの遺伝子型の決定方法 |
| EP2061805B1 (en) * | 2006-08-25 | 2020-02-12 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | Recombinant hcv e2 glycoprotein |
-
2007
- 2007-08-24 EP EP07784854.7A patent/EP2061805B1/en active Active
- 2007-08-24 US US12/438,657 patent/US8535686B2/en not_active Expired - Fee Related
- 2007-08-24 KR KR1020097005994A patent/KR101500017B1/ko not_active Expired - Fee Related
- 2007-08-24 CN CN200780036968.8A patent/CN101563362B/zh active Active
- 2007-08-24 JP JP2009525853A patent/JP5674310B2/ja not_active Expired - Fee Related
- 2007-08-24 WO PCT/AU2007/001221 patent/WO2008022401A1/en not_active Ceased
- 2007-08-24 AU AU2007288129A patent/AU2007288129B2/en active Active
- 2007-08-24 CA CA002661814A patent/CA2661814A1/en not_active Abandoned
-
2013
- 2013-08-14 US US13/967,059 patent/US9598467B2/en not_active Expired - Fee Related
-
2014
- 2014-09-11 JP JP2014185095A patent/JP5999524B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501594A5 (enExample) | ||
| US6951646B1 (en) | Anti hepatitis C virus antibody and uses thereof | |
| Goh et al. | Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model | |
| Keck et al. | Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice | |
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| JP2012504602A5 (enExample) | ||
| EA201170353A1 (ru) | Антитела против гепатита с и их применение | |
| JP2012531219A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| JP2005528914A5 (enExample) | ||
| Arribillaga et al. | Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus | |
| Zhou et al. | Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro | |
| JP2018537117A5 (enExample) | ||
| JP2008532559A5 (enExample) | ||
| JP2006504645A5 (enExample) | ||
| JP5897024B2 (ja) | 組成物および方法 | |
| JP2006523185A5 (enExample) | ||
| US20080248042A1 (en) | Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc | |
| CN105254756B (zh) | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 | |
| El-Awady et al. | Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats | |
| TWI432211B (zh) | 與登革病毒相關之胜肽及抗體以及其用途 | |
| EP2705369B1 (fr) | Procédé pour la détection d'une infection par le virus de la dengue | |
| Takao et al. | Antibody reactive to a hepatitis C virus (HCV)‐derived peptide capable of inducing HLA‐A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV‐infected individuals without HLA‐A2 restriction | |
| CN107286237B (zh) | 一种抗丙型肝炎病毒抗体的获取以及应用 | |
| CN113876939A (zh) | 登革次单位疫苗组成物 |